Tag Archive for: manufacturing

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

Paris, France, 28 November, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board. Michel joins existing Board members Jérémie Laurent, CEO; Alain Huriez, Director; AdBio Partners; Christian […]

Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan

Significant endorsement by the French government programme that promotes excellence in research and manufacturing of novel biotherapies Advances the Company’s ambitions for its Lakhesys™ platform Total company funding now over €30 Million Paris, France, October 24, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and […]

Astraveus raises €16.5 Million Series Seed round to advance the development of its automated, microfluidic Cell and Gene Therapy manufacturing platform

Company emerges from stealth with financing led by AdBio partners, co-syndicated with M Ventures, Johnson & Johnson Innovation – JJDC Inc., and Bpifrance Large Venture to advance their ground-breaking cell and gene therapy manufacturing solution World leading technology miniaturizes and automates cell and gene therapy manufacturing in a unique, modular, end-to-end, microfluidic solution that mimics […]

Futura Medical Interim Results for the Six Months ended 30 June 2022

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce its unaudited interim results for the six months ended 30 June 2022. Read more…

Futura Medical Full Year Results for the year ended 31 December 2021

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce its audited results for the year ended 31 December 2021. Read more…